OKMETIC OYJ INTERIM REPORT 1 JANUARY-31 MARCH 2014: NET SALES GROWING, STRONG DEMAND ESPECIALLY FOR SENSOR WAFERS


OKMETIC OYJ      INTERIM REPORT            24 APRIL 2014 AT 8.00 A.M.

INTERIM REPORT 1 JANUARY - 31 MARCH 2014: NET SALES GROWING, STRONG DEMAND
ESPECIALLY FOR SENSOR WAFERS

Unless otherwise stated, figures in parenthesis refer to the corresponding
period in the previous year.

JANUARY-MARCH IN BRIEF:

  * Net sales amounted to 17.4 (16.4) million euro, up 6.1%.
  * Silicon wafer shipments amounted to 17.5 (15.5) million euro, up 13.0%.
  * Operating profit was 0.9 (1.4) million euro, corresponding to 5.3% (8.4%) of
    net sales.
  * Profit for the period was 0.6 (1.2) million euro.
  * Basic earnings per share was 0.04 (0.07) euro.
  * Net cash flow from operations amounted to 0.6 (0.8) million euro.


SHORT-TERM OUTLOOK

The demand for semiconductors is expected to grow in year 2014. Also for the
silicon wafer market, volume growth is expected in 2014. However, the average
price level of wafers as well as the total value of the silicon wafer market is
expected to further decline.

Demand for Okmetic's sensor wafers is estimated to grow from the previous year,
and the sales and price levels of sensor wafers are expected to be fairly stable
throughout the year. Prices of semiconductor wafers are hit by the weakened
Japanese yen. However, the demand is expected to pick up compared to 2013. In
accordance with normal seasonal fluctuation, the demand for semiconductor wafers
is strongest in the second and third quarters of the year. Other business sales
are not expected to materially differ from the low level of year 2013.

The company retains its existing guidance, according to which net sales and
operating profit in 2014 are estimated to exceed the level of year 2013.

PRESIDENT KAI SEIKKU:

"Net sales were up compared to the corresponding period last year. The
development of net sales was particularly positive in high value-added sensor
wafers, with a more than 17-percent rise in shipments from the corresponding
period in year 2013. Sensor wafers already accounted for 63 percent of net sales
for the quarter. Shipment volumes in semiconductor wafers were also up. Other
business accounted for only a marginal share of net sales in the first quarter.

Operating profit fell in comparison to the first quarter of 2013. Comparable
profitability in silicon wafers however improved. In the reporting period,
operating profit was negatively impacted by non-operating IFRS items, which in
the same period of last year had a significant positive impact on profit
performance. Moreover, Other business sales in the first and second quarters of
2013 included substantial income from polysilicon trading. This year, the
polysilicon trading, made for purposes of working capital management, is likely
to take place in the second and third quarters of 2014. Tentatively, the company
does not foresee a significant need for this kind of inventory adjustment
anymore in the fiscal year of 2015.

Strong demand and good margins in sensor wafers improved profitability in the
silicon wafer business. Semiconductor wafer sales also showed growth, but, as
anticipated, the sales margin fell clearly short of the average for 2013 due to
the lower price level. The Allen plant was loss-making at the beginning of the
year due to demand and inventory, and this further weighed on the quarterly
operating profit.

The healthy demand of the first quarter looks set to continue in the second and
third quarters. Okmetic is enjoying strong growth in sensor wafers, thanks to
investments made over a number of years. In the beginning of the year, the
company set a record in SOI wafer sales. As anticipated, there was also strong
growth in the share of 200-millimetre wafers in key customer segments during the
reporting period. To support this development, new in-house capacity for the
production of 200-millimetre wafers will be added in the second quarter.

In semiconductor wafer sales, Okmetic focuses on discrete and power
semiconductors where it possesses a high level of expertise and long-standing
client relationships. The current price level for these wafers is challenging,
but long-term prospects are promising. The applications for electric and hybrid
vehicles (e-mobility) and green energy will require semiconductor components for
power management, current control and energy saving. In addition to its focus on
sensor wafers, Okmetic will continue its commitment to serving the discrete and
power semiconductor industries by investing in product development and
production technology."

KEY FIGURES

 1,000 euro                  1 Jan- 1 Jan- 1 Jan- 1 Jan-
                             31 Mar 31 Mar 31 Dec 31 Dec
                               2014   2013   2013   2012



 Net sales                   17,405 16,403 68,516 83,074

 Operating
 profit
 before
 depreciation
 (EBITDA)                     2,546  2,725 10,905 13,864

 Operating
 profit                         928  1,373  5,031  8,018

   % of net sales               5.3    8.4    7.3    9.7

 Profit for
 the period                     641  1,218  3,842  5,089

 Basic earnings
 per share,
 euro                          0.04   0.07   0.23   0.31

 Net cash flow
 from operating
 activities                     632    811  9,726  9,425

 Net interest-
 bearing
 liabilities                  8,898  2,003  6,530 -1,688

 Equity ratio,%                68.4   67.3   68.2   72.2

 Average number of personnel
 during the period

                                355    358    363    368


MARKETS

Customer industries

Sensor industry

The sales value of sensor industry increased by 5.8 percent in 2013 compared to
the previous year. The increasing use of micro sensors in many consumer
electronics products has accelerated sensor sales growth. In 2014, the sales
value of sensor industry is estimated to grow by 7 percent, and annual growth of
5-13 percent is forecasted for the next few years. In terms of volume, sensor
shipments are likely to clearly rise to a new record in year 2014 too. (IHS,
Yole)

Semiconductor industry

The global semiconductor industry's sales in US dollars reached a new record in
the last quarter of 2013. For the whole year 2013, the sales were 4.2 percent
higher than in the previous year, and exceeded for the first time 300 billion US
dollars (303.5 billion USD, SIA). The prices of memory circuits turned into
growth, which had a positive impact on the market.
The sales volumes in January and February were clearly higher than in 2013 (+10%
on average), but according to the seasonal fluctuation typical of the industry,
monthly sales were approximately five percent lower than in November 2013
(SEMI).

The semiconductor market is expected to continue to grow moderately during
2014. The growth estimates for the whole year settle between 3 and 7 percent
(WSTS, Cowan, Digitimes, ICInsights), and the growth is expected to continue
also in the following years (IDC). Faster sales growth than market average is
forecasted for discrete and power semiconductors, which are important to Okmetic
(IC Insights, Infiniti Research).

Silicon wafer market

According to the report of SMG, the group of silicon wafer suppliers in SEMI (a
global umbrella organisation for semiconductor materials and equipment
industry), the surface area of silicon wafer shipments in 2013 calculated in
square inches was 0.4 percent larger than in 2012. The total value of the
silicon wafer market in US dollars kept decreasing in 2013 due to declined
average sales prices and weakening of the Japanese yen. The volume of silicon
wafer shipments in January-February 2014 followed the trend in semiconductor
sales and exceeded the level of the corresponding period in 2013 (SMG).

The key customer areas for Okmetic in the silicon wafer market

In line with its strategy, Okmetic seeks niches in the silicon wafer market,
where growth exceeds market average and in which the company has special
expertise. Okmetic supplies primarily 150mm and 200mm wafers. The sensor/MEMS
industry is a key growth area for Okmetic. MEMS market grows as portable
consumer products, automotive electronics, and industrial process control
increase.

In the semiconductor market, Okmetic's growth areas include silicon wafers for
discrete and power semiconductor production. In these wafer markets, areas for
growth include, among others, components used in the production of renewable
energy, increasing automotive electronics, portable consumer products, as well
as different solutions related to power supply and efficiency improvement.

SALES

In January-March, Okmetic's net sales amounted to 17.4 (16.4) million euro. Net
sales increased by 6.1 percent (decrease of 13.2%) compared to the corresponding
period last year, due to strong demand for sensor wafers. Okmetic's market share
remained stable in product groups important to the company, and sales improved
towards the end of the first quarter.

Sales per customer area

                      1 Jan-  1 Jan- 1 Jan-  1 Jan-
                      31 Mar 31 Mar, 31 Dec 31 Dec,
                        2014    2013   2013    2012



 Sensor wafers           63%     60%    59%     47%

 Semiconductor wafers    35%     37%    37%     38%

 Other business           2%      3%     4%     15%



The demand for sensor wafers was very strong in January-March, and the value of
shipments was 17.5 percent higher than in the corresponding period last year.
Especially the demand for the strategically important SOI wafers was at a good
level. The demand for sensor wafers is estimated to remain solid throughout the
year 2014.

The semiconductor industry's demand shows signs of recovery, and the
semiconductor wafer sales as well grew in the first quarter. The value of
shipments in January-March was 5.6 percent higher than in the corresponding
period last year.

The value of Other business shipments amounted to 0.3 (0.6) million euro in
January-March.

Sales per market area

                1 Jan-  1 Jan-  1 Jan-  1 Jan-
               31 Mar, 31 Mar, 31 Dec, 31 Dec,
                  2014    2013    2013    2012



 North America     37%     39%     42%     37%

 Europe            40%     36%     40%     27%

 Asia              23%     25%     18%     35%



In the first quarter, Okmetic's sales in Europe showed strong growth. Also in
North America the sales performed well. Sales in Asia were at the same level as
in the first quarter of 2013.

PROFITABILITY

January-March

In January-March, Okmetic's operating profit amounted to 0.9 (1.4) million euro,
corresponding to 5.3 (8.4) percent of net sales. The Allen plant had a negative
stand-alone result in January-February, which had a significant effect on the
group's operating profit, as did clearly higher depreciations than in the
comparison period. In addition, IFRS entries and polysilicon trading income in
2013 explain the difference to the comparison period.
Profit for the period was 0.6 (1.2) million euro. Basic earnings per share was
0.04 (0.07) euro. Diluted earnings per share was 0.04 (0.07) euro.

FINANCING

The company's financial position is solid. In January-March, net cash flow from
operations amounted to 0.6 (0.8) million euro. Changes in working capital tied
up in operations weakened net cash flow from operations by 2.0 (2.6) million
euro.

On 31 March 2014, the company's interest-bearing liabilities amounted to 12.6
(15.9) million euro.

At the end of the period, the cash and cash equivalents amounted to 3.7 (13.9)
million euro. On 31 March 2014, the company's net interest-bearing liabilities
amounted to 8.9 million euro (2.0 million euro on 31 March 2013). The increase
in net interest-bearing liabilities is due to the five-year loan agreement of
10 million euro, signed in January 2013. The loan is used for investments and
general corporate purposes. The group has ensured liquidity with committed
credit facilities of 6.0 million euro. On 31 March 2014, two million euro of the
committed credit facilities was in use.

Return on equity amounted to 4.4 (7.8) percent. The company's equity ratio was
68.4 (67.3) percent. Equity per share was 3.46 (3.80) euro.

INVESTMENTS

In January-March, Okmetic's capital expenditure amounted to 1.1 (2.6) million
euro. The investments in the first quarter were mainly made for increasing
capacity for 200mm wafers at the Vantaa plant.

PRODUCT DEVELOPMENT

In January-March, the company expensed 0.7 (0.6) million euro in product
development projects, corresponding to 3.9 (3.9) percent of net sales. Product
development costs have not been capitalised. Emphasis in product development was
on engineered products. Focus areas include broadening the SOI product family,
improving capability in 200mm products as well as developing crystal growing to
enhance capability in high and low resistivity products.

PERSONNEL

In January-March, Okmetic employed on average 355 (358) people. At the end of
the period, Okmetic employed 354 (354) people, of which 310 worked in Finland,
38 in the US, five in Japan, and one in Hong Kong.

BUSINESS RISKS

There have been no significant changes in the company's near future business
risks and uncertainties.

Okmetic's business is confronted by risks, which may arise from the company's
operations or changes in its operating environment. Risks that, if materialized,
can have an adverse effect on the company's operations and valuation are
described below.

Okmetic's silicon wafer sales are targeted at the sensor and semiconductor
producers in the electronics industry. The demand for semiconductor wafers is
sensitive to economic fluctuations, and changes in the market situation can be
sudden and dramatic. The demand for sensor wafers is more stable. The
proliferation of sensors in consumer electronics applications may, however,
increase the susceptibility of this market too to economic fluctuations.
Okmetic has existing polysilicon purchasing obligations partly until 2015. Since
the price level of the solar cell market has dropped, the validity of long-term
polysilicon contracts typical of the industry may cause a price risk.

Okmetic's share of the global silicon wafer market is around one percent and the
market prices have a notable effect on the price development of Okmetic's
products. The company has considerable pricing power only with its own special
products. The pricing of other wafers is largely based on global market price.

Okmetic operates globally, and therefore the company's business is affected by
risks due to exchange rate fluctuations, consisting of cash flows from purchases
and sales. A significant part of sales are conducted in US dollars. Despite
hedging, the company remains exposed to exchange rate fluctuations.

Substantial volumes of electricity are used in Okmetic's production. Despite
hedging, the company is exposed to fluctuations in the price of electricity.

SHARES AND SHAREHOLDERS

On 31 March 2014, Okmetic Oyj's paid-up share capital, as entered in the Finnish
Trade Register, was 11,821,250.00 euro. The number of shares was 17,287,500. The
shares have no nominal value attached. Each share entitles its holder to one
vote at general meetings. The company has one class of shares. The company's
shares are included in the Finnish book-entry securities system.


 Major shareholders on
 31 March 2014

                                            Shares, Share,
                                                pcs      %

 Ilmarinen Mutual Pension
 Insurance Company                        1,549,985    9.0

 Oy Ingman Finance Ab                       870,000    5.0

 Mandatum Life Insurance
 Company Limited                            800,000    4.6

 The State Pension Fund                     600,000    3.5

 Nordea Nordic Small
 Cap Fund                                   528,810    3.1

 Varma Mutual Pension
 Insurance Company                          477,175    2.8

 Okmetic Oyj *)                             432,204    2.5

 Etra-Invest Oy Ab                          400,000    2.3

 Investment Fund
 Taaleritehdas Arvo Markka
 Osake                                      225,100    1.3

 Kaleva Mutual Pension Insurance Company    212,700    1.2

 Foreign investors and
 nominee accounts held by
 custodian banks                          2,898,603   16.8

 Other                                    8,292,923   48.0

 Total                                   17,287,500  100.0


*) of which 400,000 shares through Okmetic Management Oy


SHARE PRICE PERFORMANCE AND TRADING

A total of 1.1 (1.0) million shares were traded between 1 January and 31 March
2014, representing 6.4 (5.8) percent of the weighted average of share total of
17.3 (17.3) million during the period. The lowest quotation during the period
was 4.38 (4.33 euro), and the highest 5.25 (5.15) euro, with the average being
4.75 (4.71) euro. The closing quotation for the period on 31 March 2014 was
4.55 (4.53) euro. At the end of the period, the market capitalisation amounted
to 78.7 (78.3) million euro.

OWN SHARES AND DIRECTED SHARE ISSUES

In a directed share issue on 16 January 2014, Okmetic Oyj transferred a total of
150,000 own shares held by the company to President Kai Seikku (140,000 shares)
and Deputy to the President Mikko Montonen (10,000 shares). Subscription price
per share was determined using the average trading price of the company's share
weighted by trading volume in NASDAQ OMX Helsinki Oy on 16 January 2014, which
was 4.9969 euro. Total value of the deal was 749,535 euro. The decision to
transfer company's own shares was based on authorization of the Board of
Directors given by the annual general meeting on 10 April 2013.

On 13 February 2014, Okmetic Oyj's board of directors announced of its decision
to transfer a total of 11,919 own shares held by the company as a part of the
company's share-based incentive scheme for the executive management group, of
which the company gave a stock exchange release on 12 February 2013. All the
shares were issued to the members of the executive management group in deviation
from the shareholders' pre-emptive rights (directed share issue). The rewards of
the share reward programme were paid in Okmetic shares and in a monetary amount
covering taxes. The directed share issue without payment was executed in full as
there was no consideration related to the issue.

At the end of the reporting period Okmetic held 432,204 (209,406) own shares, of
which 400 000 shares through Okmetic Management Oy. The number of own shares
corresponds to 2.5 (1.2) percent of Okmetic's all shares and votes.

More information relating to own shares and directed share issues can be found
on the company website www.okmetic.com > Investors > Share information > Own
shares.

OTHER EVENTS IN THE INTERIM PERIOD

On 15 January 2014, the Board of Directors decided to dissolve the ownership
arrangement of Okmetic Management Oy, owned by President Kai Seikku and Deputy
to the President Mikko Montonen, with an arrangement in which Okmetic Oyj
acquired the entire share capital of Okmetic Management Oy. Also 400,000 shares
of Okmetic Oyj were transferred to the group via Okmetic Management Oy, as well
as a loan receivable of Okmetic Oyj from Okmetic Management Oy. There were no
shareholders of Okmetic Management Oy in the Board of Directors of Okmetic Oyj.
The value of the arrangement for the part of shares owned by Okmetic Management
Oy was determined using the average trading price weighted by trading volume of
the company's share in NASDAQ OMX Helsinki Oy on 16 January 2014, 4.9969 euro.

Mikko Montonen, Executive Vice President, Customers and Markets, Deputy to the
President, resigned from Okmetic on 26 February 2014 to assume a new position
with another company. Mr. Montonen's management responsibilities at Okmetic
ended on 6 April 2014.

Anna-Riikka Vuorikari-Antikainen, Senior Vice President, Products was appointed
Senior Vice President, Customers and Markets from 7 April 2014. Ms. Vuorikari-
Antikainen is also responsible for customer support.

Atte Haapalinna, Senior Vice President, Customer Support, was appointed Senior
Vice President, Products from 7 April 2014.

EVENTS AFTER THE END OF THE INTERIM PERIOD

Annual general meeting on 9 April 2014

Okmetic Oyj's annual general meeting, which was held on 9 April 2014, adopted
the annual accounts and the consolidated annual accounts for 2013 and discharged
the company's management from liability. The annual general meeting decided, in
accordance with the proposal of the board of directors that no dividend shall be
distributed for the financial year 2013. Moreover, the general meeting approved
the proposal of the board of directors to authorise the board of directors to
decide on the repurchase and/or the acceptance as pledge of the company's own
shares as well as on the issuance of shares, the transfer of the company's own
shares, and the issuance of special rights entitling to shares.

It was decided that there will be five members on the company's board of
directors. Mr. Hannu Martola, Ms. Mervi Paulasto-Kröckel, Mr. Mikko Puolakka,
and Mr. Henri Österlund were re-elected as members of the board of directors and
Mr. Jan Lång was elected as new board member until the end of the next annual
general meeting. The board of directors elected Henri Österlund as its chairman
and Jan Lång as its vice chairman in its organising meeting held immediately
after the annual general meeting.

Authorised Public Accountant PricewaterhouseCoopers Oy was elected as auditor,
with APA Mikko Nieminen having the principal responsibility.

Authorisations given to the board of directors and other decisions of the annual
general meeting have been disclosed in a stock exchange release published on 9
April 2014.


CONDENSED FINANCIAL STATEMENTS AND TABLES 1 JANUARY - 31 MARCH 2014 (unaudited)

ACCOUNTING POLICIES

These interim financial statements have been prepared in accordance with IAS
34, Interim Financial Reporting.

In preparing these interim financial statements, Okmetic has followed the same
accounting policies as in the financial statements for 2013 except for the
effect of changes required by the adoption of certain new or revised IFRS
standards and IFRIC interpretations as of 1 January 2014, which have been
described in financial statements 2013. The adoption of the new and revised
standards and interpretations has not had an effect on the figures presented
from the reporting period.

CONDENSED CONSOLIDATED STATEMENT OF COMPREHENSIVE INCOME

 1,000 euro      1 Jan-  1 Jan-  1 Jan-
                31 Mar, 31 Mar, 31 Dec,
                   2014    2013    2013



 Net sales       17,405  16,403  68,516

 Cost of sales  -14,072 -13,118 -54,918

 Gross profit     3,333   3,285  13,598

 Other income
 and expenses    -2,405  -1,911  -8,567

 Operating          928   1,373   5,031
 profit

 Financial
 income and
 expenses           -36     -97    -630

 Profit before
 tax                892   1,277   4,401

 Income tax        -251     -58    -559

 Profit for
 the period         641   1,218   3,842



 Other
 comprehensive
 income:

 Items that may
 be
 reclassified
 to profit or
 loss in
 subsequent
 periods

 Cash flow
 hedges             -20     -47     -58

 Translation
 differences         -3     316     -60

 Other
 comprehensive
 income for the
 period, net of
 tax                -23     269    -118



 Total
 comprehensive
 income for
 the period         618   1,487   3,724



 Profit for the
 period
 attributable
 to:

 Equity holders
 of the parent
 company            641   1,218   3,842



 Total
 comprehensive
 income
 attributable
 to:

 Equity holders
 of the parent
 company            618   1,487   3,724



 Basic earnings
 per share,
 euro              0.04    0.07    0.23

 Diluted
 earnings per
 share, euro       0.04    0.07    0.22




CONDENSED CONSOLIDATED BALANCE SHEET

 1,000 euro             31 Mar, 31 Mar, 31 Dec,
                           2014    2013    2013



 Assets



 Non-current assets

 Property, plant and
 equipment               44,827  44,819  45,295

 Intangible assets          881     739     897

 Other receivables        1,420   2,712   1,419

 Total non-current
 assets                  47,128  48,270  47,611



 Current assets

 Inventories             17,898  15,760  16,634

 Receivables             16,826  16,371  14,572

 Cash and cash            3,748  13,859   5,214
 equivalents

 Total current
 assets                  38,472  45,990  36,420



 Total assets            85,600  94,260  84,031



 Equity and liabilities

 Equity

 Equity attributable
 to equity holders of
 the parent company

 Share capital           11,821  11,821  11,821

 Other equity            46,507  51,605  45,451

 Total equity            58,328  63,426  57,273



 Liabilities

 Non-current
 liabilities              9,540  12,950  10,533

 Current liabilities     17,731  17,884  16,226

 Total liabilities       27,271  30,834  26,759



 Total equity and
 liabilities             85,600  94,260  84,031






CONDENSED CONSOLIDATED CASH FLOW STATEMENT

 1,000 euro                        1 Jan-  1 Jan-  1 Jan-
                                  31 Mar, 31 Mar, 31 Dec,
                                     2014    2013    2013



 Cash flows from operating
 activities:

 Profit before tax                    892   1,277   4,401

 Adjustments                        1,705   1,223   6,566

 Change in working capital         -1,954  -2,626  -2,091

 Financial items                      -77     -13    -126

 Tax paid                              67     950     976

 Net cash from
 operating activities                 632     811   9,726



 Cash flows from investing
 activities:

 Purchases of property,
 plant and equipment               -1,637  -4,131  -9,089

 Net cash used in
 investing activities              -1,637  -4,131  -9,089



 Cash flows from financing
 activities:

 Proceeds from long-
 term borrowings                        -  10,000  10,000

 Proceeds from short-
 term borrowings                    4,000      23   1,024

 Payments of long-term borrowings
                                   -1,000       -  -1,000


 Payments of short-
 term borrowings                   -2,024       -  -4,043



 Payments of finance
 lease liabilities                   -138    -109    -478

 Other items                           36       -      10



 Dividends paid                      -578       -  -6,763

 Capital repayment                      -       -  -1,169

 Management
 arrangement's
 dissolvement                        -768       -       -

 Net cash used in
 financing activities                -472   9,904  -2,419

 Increase (+) /
 decrease (-) in cash
 and cash equivalents              -1,477   6,585  -1,782

 Exchange rate changes                 11     -14    -292

 Cash and cash
 equivalents at
 the beginning
 of the period                      5,214   7,288   7,288

 Cash and cash
 equivalents at
 the end of the
 period                             3,748  13,859   5,214








CONSOLIDATED STATEMENT OF CHANGES IN EQUITY

              Equity attributable to equity holders of parent company

                Share  Share  Reserve  Other Retained           Total
              capital   pre-  for in-    re- earnings
                        mium   vested serves
 1,000 euro                     unre-     1)
                             stricted
                               equity

 Balance at
 31 Dec, 2013  11,821 20,045        3  1,756   23,647          57,273

 Profit for
 the period                                       641             641

 Other com-
 prehensive
 income, net
 of tax:

 Cash flow
 hedges                                  -20                      -20

 Translation
 differences                              -3                       -3

 Total com-
 prehensive
 income for
 the period                              -23      641             618



 Share issue                      750                             750



 Share-based
 payments                                          45              45

 Acquisition
 of non-
 controlling
 interest                                        -357            -357





 Balance at
 31 Mar, 2014  11,821 20,045      753  1,732   23,977          58,328



 Balance at
 31 Dec, 2012  11,821 20,045    1,200  1,874   26,919          61,860

 Profit for
 the period                                     1,218           1,218

 Other com-
 prehensive
 income, net
 of tax:

 Cash flow
 hedges                                  -47                      -47

 Translation
 differences                             316                      316

 Total com-
 prehensive
 income for
 the period                              269    1,218           1,487



 Share-based
 payments                                          80              80

 Balance at
 31 Mar, 2013  11,821 20,045    1,200  2,143   28,217          63,426


1)"Other reserves" contains hedge reserve and translation differences.

Acquisition of shares of Okmetic Management Oy is treated as acquisition of non-
controlling interest.


CHANGES IN PROPERTY, PLANT AND EQUIPMENT

 1,000 euro            1 Jan-  1 Jan-  1 Jan-
                      31 Mar, 31 Mar, 31 Dec,
                         2014    2013    2013



 Carrying amount
 at the beginning
 of the period         45,295  43,433  43,433

 Additions              1,068   2,569   7,648

 Disposals                  -       -      -9

 Depreciation          -1,538  -1,302  -5,623

 Exchange differences       2     119    -154

 Carrying amount
 at the end of
 the period            44,827  44,819  45,295



COMMITMENTS AND CONTINGENCIES

 1,000 euro                  31 Mar, 31 Mar, 31 Dec,
                                2014    2013    2013



 Loans, secured with
 collaterals                   9,000  11,000  10,000

 Collaterals                  17,128  21,164  17,128

 Off-balance sheet
 lease commitments               395     453     395



 Capital commitments           1,293   2,376   1,910



 Nominal values of
 derivative contracts

 Currency
 forward
 agreements                    1,963     769   1,144

 Currency options,
 call                            646     895     948

 Currency options,
 put                              72       -     182

 Electricity
 derivatives                   1,657   2,434   1,847


 Fair values of
 derivative contracts

 Currency forward agreements
                                   5     -11      20

 Currency options, call            4       2      12

 Currency options, put            -1       -      -1
 Electricity

 derivatives                    -420    -199    -350


The contract price of the derivatives has been used as the nominal value of the
underlying asset.

HIERARCHY LEVELS OF DERIVATIVE CONTRACTS MEASURED AT FAIR VALUE

 1,000 euro    31 Mar, 2014        31 Mar, 2013

             Level Level Level   Level Level Level
                 1     2     3       1     2     3

 Financial
 assets

 Derivative
 financial
 instruments     -   107     -       -    31     -



 Financial
 liabilities

 Derivative
 financial
 instruments     -   519     -       -   240     -


Fair value estimation

The  group's  financial  instruments  that  are  measured at fair value comprise
derivatives  used for hedging and  held for trading, and  they are classified on
hierarchy level 2.

Fair values of level 2 instruments are based on other data than quoted prices in
active markets, but on the data from which the asset is observable, either
directly (i.e. price) or indirectly (i.e. derived from the prices).

Fair value determination

The fair values of currency derivatives are determined by using mark-to-market
method at the reporting date.

The fair values of electricity derivatives are determined on the basis of market
quotations and contract prices of the instruments at the reporting date.

KEY FIGURES SHOWING FINANCIAL PERFORMANCE

 1,000 euro                1 Jan-  1 Jan-  1 Jan-
                          31 Mar, 31 Mar, 31 Dec,
                             2014    2013    2013



 Net sales                 17,405  16,403  68,516

 Change in net sales
 compared to the previous
 year's period, %             6.1   -13.2   -17.5

 Export and foreign
 operations share
 of net sales, %             88.3    92.5    91.8

 Operating profit before
 depreciation (EBITDA)      2,546   2,725  10,905

     % of net sales          14.6    16.6    15.9

 Operating profit             928   1,373   5,031

     % of net sales           5.3     8.4     7.3

 Profit before tax            892   1,277   4,401

     % of net sales           5.1     7.8     6.4

 Return on equity, %          4.4     7.8     6.4

 Return on investment, %      5.4     6.6     6.7

 Non-interest-bearing
 liabilities               14,625  14,972  15,014

 Net interest-bearing
 liabilities                8,898   2,003   6,530

 Net gearing ratio, %        15.3     3.2    11.4

 Equity ratio, %             68.4    67.3    68.2

 Capital expenditure        1,068   2,569   7,648

     % of net sales           6.1    15.7    11.2

 Depreciation               1,618   1,352   5,874

 Research and development
 expenditure                  672     644   2,779

     % of net sales           3.9     3.9     4.1



 Average number of
 personnel during             355     358     363
 the period

 Personnel at the
 end of the period            354     354     355




KEY FIGURES PER SHARE

When calculating equity per share, Okmetic's own shares and Okmetic shares owned
by Okmetic Management Oy are deducted from the total number of shares.


 Euro                        31 Mar, 31 Mar, 31 Dec,
                                2014    2013    2013

 Basic earnings
 per share                      0.04    0.07    0.23

 Diluted earnings
 per share                      0.04    0.07    0.22

 Equity per share               3.46    3.80    3.43

 Capital repayment per share
                                   -       -    0.07

 Dividend per share                -       -       -

 Dividends/earnings, %             -       -       -

 Effective dividend
 yield, %                          -       -       -

 Price/earnings(P/E)               -       -    20.9



 Share performance
 (1.1.-)

 Average trading price          4.75    4.71    4.92

 Lowest trading price           4.38    4.33    4.25

 Highest trading price          5.25    5.15    5.66

 Trading price at the
 end of the period              4.55    4.53    4.82

 Market capitalisation
 at the end of the
 period, 1,000 euro           78,658  78,312  83,326


 Trading volume (1 Jan-)

 Trading volume,
 transactions, 1,000 pcs       1,105   1,004   3,382

 In relation to weighted
 average number of
 shares, %                       6.4     5.8    19.6

 Trading volume,
 1,000 euro                    5,286   4,732  16,647

 The weighted average
 number of shares during
 the period under review
 adjusted by the share
 issue, 1,000 pcs             17,288  17,288  17,288

 The number of shares at
 the end of the period
 adjusted by the share
 issue, 1,000 pcs             17,288  17,288  17,288



QUARTERLY KEY FIGURES

 1,000 euro                  10-12/ 7-9/ 4-6/   1-3/
                               2014 2014 2014   2014



 Net sales                                    17,405

   Compared to previous
   quarter, %                                    3.4

   Compared to corresponding
   period last year, %                           6.1

 Operating profit                                928

   % of net sales                                5.3

 Profit before tax                               892

   % of net sales                                5.1



 Net cash flow generated
 from:
 Operating activities                            632

 Investing activities                         -1,637

 Financing activities                           -472

 Increase/decrease in cash
 and cash equivalents                         -1,477



 Personnel at the end
 of the period                                   354


 1,000 euro                  10-12/   7-9/   4-6/   1-3/
                               2013   2013   2013   2013



 Net sales                   16,837 18,242 17,035 16,403

   Compared to previous
   quarter, %                  -7.7    7.1    3.9  -20.7

   Compared to corresponding
   period last year, %        -18.6  -13.2  -24.2  -13.2

 Operating profit               263  1,423  1,971  1,373

   % of net sales               1.6    7.8   11.6    8.4

 Profit before tax               32  1,280  1,812  1,277

   % of net sales               0.2    7.0   10.6    7.8



 Net cash flow generated
 from:
 Operating activities         4,915  3,481    519    811

 Investing activities        -1,304 -1,687 -1,966 -4,131

 Financing activities        -3,892 -1,155 -7,276  9,904

 Increase/decrease in cash
 and cash equivalents          -281    639 -8,724  6,585



 Personnel at the end
 of the period                  355    356    379    354



DEFINITIONS OF KEY FINANCIAL FIGURES




 Operating profit before             = Operating profit + depreciation
 depreciation (EBITDA)



 Return on equity (ROE), %           = Profit/loss for the period x 100/
                                      -----------------------------------------
                                       Equity(Average for the period)



 Return on investment (ROI), %       = (Profit/loss before tax + interest and
                                       other financial expenses) x 100/
                                      -----------------------------------------
                                       Balance sheet total - non-interest
                                       bearing liabilities(average for the
                                       period)



 Equity ratio, %                     = Equity x 100/
                                      -----------------------------------------
                                       Balance sheet total - advances received



 Net interest-bearing liabilities    = Interest-bearing liabilities - cash and
                                       cash equivalents



 Net gearing ratio, %                = (Interest-bearing liabilities - cash and
                                       cash equivalents) x 100/
                                      -----------------------------------------
                                       Equity



 Earnings per share                  = Profit/loss for the period attributable
                                       to  equity holders of the parent
                                       company/
                                      -----------------------------------------
                                       Adjusted weighted average number of
                                       shares in issue during the period



 Equity per share                    = Equity attributable to equity holders of
                                       the parent company/
                                      -----------------------------------------
                                       Adjusted number of shares at the end of
                                       the period



 Dividend per share                  = Dividend for the period/
                                      -----------------------------------------
                                       Adjusted number of shares at the end of
                                       the period



 Effective dividend yield, %         = Dividend per share x 100/
                                      -----------------------------------------
                                       Trading price at the end of the period



 Price/earnings ratio (P/E)          = Last adjusted trading price at the end
                                       of the period/
                                      -----------------------------------------
                                       Earnings per share



 Average trading price               = Total traded amount in euro/
                                      -----------------------------------------
                                       Adjusted number of shares traded during
                                       the period



 Market capitalisation at the end of = Number of shares at the end of the
 the period                            period x trading price at the end of the
                                       period



 Trading volume                      = Number of shares traded during the
                                       period/
                                      -----------------------------------------
                                       Weighted average number of shares during
                                       the period


All figures of the financial tables are rounded, and consequently the sum of
individual figures can deviate from the presented sum figure.

The future estimates and forecasts in this interim report are based on the
company management's current knowledge. Actual events and results may differ
from the estimates presented here.


NEWS CONFERENCE

A briefing for analysts, investors and media will take place on Thursday, 24
April 2014 at 8.30 a.m. in Helsinki Stock Exchange building, Fabianinkatu 14,
Helsinki, (entrance via NASDAQ OMX's reception, 2(nd) floor). In the event,
Okmetic's President Kai Seikku will present the group's performance in Q1 2014.
Welcome!


OKMETIC OYJ

Board of directors

For further information, please contact:

President Kai Seikku, Okmetic Oyj,
tel. +358 5028 0232, email: kai.seikku@okmetic.com

Senior Vice President, Finance, IT, and Communications
Juha Jaatinen, Okmetic Oyj, tel. +358 9 5028 0286,
email: juha.jaatinen@okmetic.com

Distribution:
NASDAQ OMX Helsinki
Principal media
www.okmetic.com

OKMETIC IN BRIEF

Okmetic is a technology company which supplies tailor-made silicon wafers for
sensor and semiconductor industries and sells its technological expertise.
Okmetic provides its customers with solutions that boost their competitiveness
and profitability.

Okmetic's silicon wafers are part of a further processing chain that produces
end products that improve human interaction and quality of life. Okmetic's
products are based on high-tech expertise that generates added value for
customers, innovative product development and an extremely efficient production
process.

Okmetic has a global customer base and sales network, production plants in
Finland and the US and contract manufacturers in Japan and China. Okmetic's
shares are listed on NASDAQ OMX Helsinki under the code OKM1V. For more
information on the company, please visit our website at www.okmetic.com.

[HUG#1779246]

Attachments

Okmetic_Interim_Report_Q114.pdf